Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8477)
All Articles published online
|
Publishing Process of This Article
|
Jan 15, 2020 (publication date) through Dec 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mizrahi JD, Gunchick V, Mody K, Xiao L, Surapaneni P, Shroff RT, Sahai V. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J Gastrointest Oncol 2020; 12(1): 83-91 [PMID: 31966916 DOI: 10.4251/wjgo.v12.i1.83] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i1/83.htm |
| Number | Citing Articles |
| 1 |
Kanglian Zheng, Xiaodong Wang, Guang Cao, Liang Xu, Xu Zhu, Liqiang Fu, Shijie Fu, Haihui Cheng, Renjie Yang. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer. CardioVascular and Interventional Radiology 2021; 44(2): 271 doi: 10.1007/s00270-020-02661-9
|
| 2 |
Zarmina S Khankhel, Sarah Goring, Sarah Bobiak, Francois-Xavier Lamy, Dweeti Nayak, Jamie Garside, Emily S Reese, Nancy Schoenherr. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncology 2022; 18(18): 2321 doi: 10.2217/fon-2021-1302
|
| 3 |
Nicolas Roussot, Julie Vincent, Remi Palmier, Guillaume Constantin, Leila Bengrine, Jean-David Fumet, François Ghiringhelli. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1293670
|
| 4 |
Ioannis A. Voutsadakis, Stefania Kokkali, Antonia Digklia. Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer 2024; 23(4): 318 doi: 10.1016/j.clcc.2024.05.009
|
| 5 |
Gabriel Allo, Ahu Can, Roger Wahba, Nils Vogel, Tobias Goeser, Fabian Kütting, Dirk Waldschmidt. Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil in advanced biliary tract cancers. Molecular and Clinical Oncology 2021; 16(2) doi: 10.3892/mco.2021.2485
|
| 6 |
Kristen Bibeau, Luis Féliz, Christine F. Lihou, Haobo Ren, Ghassan K. Abou-Alfa. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precision Oncology 2022; (6) doi: 10.1200/PO.21.00414
|
| 7 |
Maria A. Gonzalez-Carmona, Christian Möhring, Robert Mahn, Taotao Zhou, Alexandra Bartels, Farsaneh Sadeghlar, Maximilian Bolch, Annabelle Vogt, Dominik J. Kaczmarek, Dominik J. Heling, Leona Dold, Jacob Nattermann, Vittorio Branchi, Hanno Matthaei, Steffen Manekeller, Jörg C. Kalff, Christian P. Strassburg, Raphael U. Mohr, Tobias J. Weismüller. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-021-04297-2
|
| 8 |
Massimiliano Salati, Alessandro Rizzo, Valeria Merz, Carlo Messina, Caputo Francesco, Fabio Gelsomino, Andrea Spallanzani, Angela Dalia Ricci, Andrea Palloni, Giorgio Frega, Stefania De Lorenzo, Pietro Carotenuto, Elisa Pettorelli, Stefania Benatti, Gabriele Luppi, Davide Melisi, Giovanni Brandi, Massimo Dominici. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert Review of Gastroenterology & Hepatology 2022; 16(1): 73 doi: 10.1080/17474124.2022.2017772
|
| 9 |
Christian Müller, Jazan Omari, Konrad Mohnike, Caroline Bär, Maciej Pech, Verena Keitel, Marino Venerito. Multidisciplinary Treatment of Patients with Progressive Biliary Tract Cancer after First-Line Gemcitabine and Cisplatin: A Single-Center Experience. Cancers 2023; 15(9): 2598 doi: 10.3390/cancers15092598
|
| 10 |
Carolina Liguori, Cecilia Copparoni, Cristiano Felicetti, Federica Pecci, Alessio Lupi, Giada Pinterpe, Rossana Berardi, Riccardo Giampieri. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study. Current Oncology 2023; 30(1): 1032 doi: 10.3390/curroncol30010079
|
| 11 |
Bei Yue, Ruiyang Gao, Zhengtao Wang, Wei Dou. Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy. Frontiers in Cellular and Infection Microbiology 2021; 11 doi: 10.3389/fcimb.2021.710945
|
| 12 |
Kanglian Zheng, Shijie Fu, Boyu Leng, Yong Cui, Renjie Yang, Guang Cao, Liang Xu, Wen-Qing Li, Ying Li, Xu Zhu, Song Gao, Peng Liu, Xiaodong Wang. Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers. Insights into Imaging 2022; 13(1) doi: 10.1186/s13244-022-01188-6
|